DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece

Recruiting

Conditions: Moderate Psoriasis
Psoriasis
Moderate Plaque Psoriasis

First Posted Date: 2024-02-07

Last Posted Date: 2025-04-13

Lead Sponsor: AbbVie

Target Recruit Count: 250

Registration Number: NCT06247319

Locations: 🇬🇷
Iatriko Psichikou /ID# 272851, Athens, Attiki, Greece
🇬🇷
University General Hospital Attikon /ID# 263442, Athens, Attiki, Greece
🇬🇷
General Hospital Andreas Syggros /ID# 266248, Athens, Attiki, Greece

and more 18 locations

Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

Phase 3

Active, not recruiting

Conditions: Migraine

Interventions: Drug: Atogepant
Drug: Placebo for Atogepant

First Posted Date: 2024-02-05

Last Posted Date: 2025-04-10

Lead Sponsor: AbbVie

Target Recruit Count: 1300

Registration Number: NCT06241313

Locations: 🇵🇹
Unidade Local de Saude de Santo Antonio, E.P.E. /ID# 258140, Porto, Portugal
🇭🇺
Semmelweis Egyetem /ID# 258800, Budapest, Hungary
🇭🇺
UNO Medical Trials /ID# 259186, Budapest, Hungary

and more 145 locations

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Livmoniplimab
Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Budigalimab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2024-02-01

Last Posted Date: 2025-05-22

Lead Sponsor: AbbVie

Target Recruit Count: 840

Registration Number: NCT06236438

Locations: 🇺🇸
Moores Cancer Center /ID# 267782, La Jolla, California, United States
🇺🇸
Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States
🇺🇸
Bond Clinic /ID# 262611, Winter Haven, Florida, United States

and more 53 locations

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Subcutaneous (SC) ABBV-383
Drug: Intravenous (IV) ABBV-383

First Posted Date: 2024-01-25

Last Posted Date: 2025-04-15

Lead Sponsor: AbbVie

Target Recruit Count: 55

Registration Number: NCT06223516

Locations: 🇺🇸
Wisconsin Medical Center /ID# 261085, Milwaukee, Wisconsin, United States
🇺🇸
Mayo Clinic Arizona /ID# 260799, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic /ID# 262808, Jacksonville, Florida, United States

and more 12 locations

A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Phase 4

Completed

Conditions: Upper Facial Lines

Interventions: Drug: BOTOX

First Posted Date: 2024-01-23

Last Posted Date: 2025-01-10

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT06218251

Locations: 🇺🇸
Skin Wellness Dermatology - Homewood /ID# 248469, Birmingham, Alabama, United States
🇺🇸
The Research Center at The Maas Clinic /ID# 256633, San Francisco, California, United States
🇺🇸
Pacific Clinical Innovations /ID# 248467, Vista, California, United States

and more 7 locations

A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

Phase 3

Active, not recruiting

Conditions: Forehead Lines

Interventions: Drug: Placebo
Drug: BOTOX

First Posted Date: 2023-12-18

Last Posted Date: 2024-04-17

Lead Sponsor: AbbVie

Target Recruit Count: 140

Registration Number: NCT06174688

Locations: 🇨🇳
Peking University First Hospital /ID# 249912, Xicheng District, Beijing, China
🇨🇳
West China Hospital, Sichuan University /ID# 250474, Chengdu, Sichuan, China
🇨🇳
Beijing Hospital /ID# 250059, Beijing, Beijing, China

and more 9 locations

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: ABBV-303
Drug: Budigalimab

First Posted Date: 2023-12-06

Last Posted Date: 2024-10-08

Lead Sponsor: AbbVie

Target Recruit Count: 192

Registration Number: NCT06158958

Locations: 🇺🇸
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 256943, New York, New York, United States
🇺🇸
City of Hope /ID# 254303, Duarte, California, United States
🇺🇸
City of Hope at Orange County Lennar Foundation Cancer Center /ID# 266792, Irvine, California, United States

and more 15 locations

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Phase 1

Recruiting

Conditions: Immunoglobulin Light Chain (AL) Amyloidosis

Interventions: Drug: ABBV-383 (Etentamig)

First Posted Date: 2023-12-06

Last Posted Date: 2025-04-29

Lead Sponsor: AbbVie

Target Recruit Count: 76

Registration Number: NCT06158854

Locations: 🇦🇺
Box Hill Hospital /ID# 255199, Box Hill, Victoria, Australia
🇫🇷
CHU Limoges - Dupuytren 1 /ID# 255370, Limoges CEDEX 1, Franche-Comte, France
🇫🇷
CHU Toulouse - Hopital Rangueil /ID# 255377, Toulouse, Haute-Garonne, France

and more 17 locations

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Etentamig
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Elotuzumab
Drug: Selinexor
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2023-12-06

Last Posted Date: 2025-05-15

Lead Sponsor: AbbVie

Target Recruit Count: 380

Registration Number: NCT06158841

Locations: 🇺🇸
University of Alabama at Birmingham - Main /ID# 261434, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Hospital - Phoenix /ID# 263326, Phoenix, Arizona, United States
🇺🇸
Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States

and more 139 locations

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Phase 1

Completed

Conditions: Moderate to Severe Glabellar Lines

Interventions: Drug: Placebo
Drug: AGN-151586

First Posted Date: 2023-11-30

Last Posted Date: 2024-04-04

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT06151561

Locations: 🇯🇵
Tokyo Center Clinic /ID# 257898, Central District, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy